

MATERIAL SAFETY DATA SHEET

Product: **BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION** Page 1 of 2
Brand Name: **VIVACAINE®** (Bupivacaine Hydrochloride and Epinephrine 1:200,000; Injection)
Revision Date: March 09, 2007

SECTION 1 GENERAL INFORMATION:

MANUFACTURER: Novocol Pharmaceutical of Canada, Inc.
P. O. Box 68
Cambridge, Ontario, Canada
N1R 5S9

SECTION 2 INFORMATION ON INGREDIENTS:

Components:	CAS #	OSHA PEL:	ACGIH TLV:	Other Recommended Limits:
Bupivacaine Hydrochloride	73360-54-0	Not Listed	Not Listed	Not Listed
Epinephrine*	51-43-4	Not Listed	Not Listed	Not Listed

*Listed as a hazardous product in the RCRA (EPA) and CERLA (EPA) regulations. However, the concentrations of Epinephrine in these products are extremely low (1:200,000)

SECTION 3 CHEMICAL PHYSICAL CHARACTERISTICS:

Boiling Point: 100°C
Vapor Pressure: 17mmHg @20°C
Vapor Density: 0.6
Specific Gravity: 1
Melting Point: 0°C
Evaporation Rate: 1
Solubility in Water: soluble
Appearance and Odour: Clear, odourless solution
Packaging: USP TYPE 1 glass cartridges with rubber stopper and cap

SECTION 4 FIRE/EXPLOSION HAZARD DATA:

Flash Point: Not flammable; product is water based
Flammable Limits: (STP)
LEL: N/A *UEL:* N/A
Extinguishing Media: N/A
Special Fire Fighting Procedures: None
Special Fire and Explosion Hazards: None

SECTION 5 REACTIVITY DATA:

Stability: Stable
Incompatibility: Compounds which react violently with water
Hazardous Decomposition or Byproducts: None
Hazardous Polymerization: Will not occur
Conditions to Avoid: None

MATERIAL SAFETY DATA SHEET

Product: **BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION** Page 2 of 2
Brand Name: **VIVACAINE®** (Bupivacaine Hydrochloride and Epinephrine 1:200,000; Injection)
Revision Date: March 09, 2007

SECTION 6 HEALTH AND HAZARD DATA:

Routes of Entry - Inhalation: No
Eyes: Yes
Skin: Yes
Ingestion: Yes

Health Hazards: Avoid ingestion and systemic absorption. Possible toxic effects on the Central Nervous System, Cardiovascular System or Allergic Reaction may occur. Avoid contact with eyes and mucous membranes.

Carcinogenicity: Not listed

Signs & Symptoms of Exposure: Systemic effects may include excitability, nervousness, confusion and drowsiness.

Medical Conditions: Avoid use in individuals with hypersensitivity to local anesthetics of the Amide Type. Use with caution in individuals with Diabetes and/or severe Hypertension..

CONSULT PRODUCT INSERT FOR CLINICAL AND PHARMOCOLOGICAL INFORMATION

SECTION 7 FIRST AID MEASURES:

Inhalation: N/A
Skin and Eye contact: Flush area with warm water
Ingestion: Seek immediate medical attention

SECTION 8 SAFE HANDLING AND DISPOSAL INFORMATION:

Steps to Take in Case of Spill: Clean up spills with normal procedures used for non-hazardous liquids. Absorb spill with inert material, then place in a chemical waste container. Clean surface thoroughly with water to remove residual contamination.

Waste Disposal Method: Dispose as a non-hazardous waste.

Precautions when Handling and Storing: Store in a cool, dry place. Avoid extremes in temperature. Handle with care to avoid breakage.

Other Precautions: Caution against ingestion and contact with eyes is recommended.

SECTION 9 CONTROL MEASURES:

Respiratory Protection: none required under normal conditions of use

Ventilation: none required under normal conditions of use

Protective Gloves: none normally required; recommended for cleanup of spills

Eye Protection: goggles/safety glasses recommended as a precaution

RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE AVAILABLE DURING DENTAL PROCEDURES

DISCLAIMER

Information and statements contained in this document have been obtained from manufacturers, suppliers and recognized reference sources as provided to or obtained by Novocol Pharmaceutical of Canada, Inc.

Novocol Pharmaceutical of Canada, Inc. believes the information to be reliable but expressly disclaims any liability for providing such information and toxicology to our customers.